{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-218611","form_type":"8-K","ticker":"IOBTQ","cik":"0001865494","company_name":"IO Biotech, Inc.","filed_at":"2022-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:57.534648+00:00","generated_at":"2026-06-24T01:08:07.280291+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"IO Biotech reports Q2 net loss of $18.5M; cash $170.1M to fund data readouts into mid-2024","bullets":["Net loss $18.5M for Q2 2022 vs $38.4M in Q2 2021, driven by higher R&D and G&A costs.","R&D expenses $12.2M (up from $6.7M) due to Phase 3 trial initiation and increased headcount.","Cash and equivalents $170.1M at June 30, 2022, down from $211.5M at Dec 31, 2021.","Initiated Phase 3 IOB-013/KN-D18 trial of IO102-IO103 + pembrolizumab in advanced melanoma.","Phase 2 basket trial (IOB-022/KN-D38) dosing started; preliminary data expected H2 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-218611","json":"https://secwatch.observer/filing/0001193125-22-218611.json","markdown":"https://secwatch.observer/filing/0001193125-22-218611.md","text":"https://secwatch.observer/filing/0001193125-22-218611.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1865494/000119312522218611/0001193125-22-218611-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1865494/000119312522218611/d359264d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T01:08:07.280291+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}